A novel chronic cirrhosis TAA-induced model in rats

Brazilian Journal of Veterinary Pathology

Volumn 3, Issue 1, 2010, Pages 9-16

  Guerra, Ricardo R ^a   Trotta, Maurício R ^b   Aloia, Thiago P A ^b   Dagli, Maria L Z ^b   Hernandez Blazquez, Francisco J ^b  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal model; Fibrosis; Rat; Shronic cirrhosis; Thioacetamide.

Indexed keywords

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 79952402798     PISSN: None     EISSN: 1983-024     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. AKAHOSHI T., HASHIZUME M., TANOUE K., SHIMABUKURO T., GOTOH N., TOMIKAWA M., SUGIMACHI K. Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor β-1. J. Gastroentero.l Hepato.l, 2002, 17, 59-65. (Pubitemid 34304388)
2. BANCROFT JD., GAMBLE M. Theory and practice of histological techniques. 5. ed. Edinburgh: Churchill Livingstone. 2004.
3. CONSTANTINOU M., THEOCHARIS SE., MIKROS E. Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats. Toxicol. Appl. Pharmacol., 2007, 218, 11-9. (Pubitemid 46026839)
4. CORBIN IR., MINUK GY. Serial Percutaneous Liver Biopsies in Laboratory Rats. Dig. Dis. Sci., 2003, 48, 1939-43. (Pubitemid 37410080)
5. CHU CJ., CHANG CC., WANG TF., LEE FY., CHANG FY., CHEN YC., CHAN CC., HUANG HC., WANG S., LEE SD. Detrimental effects of nitric oxide inhibition on hepatic encephalopathy in rats with thioacetamide-induced fulminant hepatic failure: Role of nitric oxide synthase isoforms. Hepatology, 2006, 21, 1194-99.
6. DEKEL R., ZVIBEL I., BRILL S., BRAZOVCKI E., HALPERN Z., OREN R. Gliotoxin Ameliorates Development of Fibrosis and Cirrhosis in a Thioacetamide Rat Model. Dig. Dis. Sci., 2003, 48, 1642-47. (Pubitemid 36936704)
7. DIAZ-GIL JJ., MUNOZ J., ALBILLOS A., RÚA C., MACHIN C., GARCIA-CAÑERO R., CARECEDA RM., GUIJARRO MC., TRILLA C., ESCARTIN P. Improvement in liver fibrosis, functionality and hemodynamics in CCl-cirrhotic rats after injection of the Liver Growth Factor. J. Hepatol., 1999, 30, 1065-72. (Pubitemid 29278751)
8. HATAKEYAMA Y., ONO T., SATO N., SAKUMA H., KOYAMA Y., INOUE N., TAKENOSHITA S., OMATA S. Usefulness of the tactile sensor for estimating the degree of liver fibrosis and the DNA synthesis activity of remnant liver cells after partial hepatectomy. Fukushima J. Med. Sci., 2002, 48, 93-101.
9. IIMURO Y., NISHIO T., MORIMOTO T., NITTA T., STEFANOVI B., CHOI SK., BRENNER DA., YAMAOKA Y. 2003. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology, 2003, 124, 445-58. (Pubitemid 36169261)
10. JANG JH., KANG KJ., KIM YN., KANG YN., LEE IS. Reevaluation of Experimental model of hepatic fibrosis induced by hepatotoxic drugs: an easy, applicable, and reproducible model. Transplant. Proc., 2008, 40, 2700-3.
11. JUNQUEIRA LCU. Picrossirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J., 1979, 11, 447-55. (Pubitemid 9238595)
12. KARANTONIS HC., GRIBILAS G., STAMOULIS I., GIAGINIS C., SPILIOPOULOU C., KOURAKLIS G., DEMOPOULOS C., THEOCHARIS SE. Platelet-Activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis. Dig. Dis. Sci., 2009, doi: 10.1007/s10620-009-0745-0.
13. KHANNA SD., PURI D. The hepatotoxic effects of dimethylnitrosamine in the rat. J. Pathol. Bacteriol., 1966, 1, 605-8.
14. LALEMAN W., ELST IV., ZEEGERS M., SERVAES R., LIBBRECHT L., ROSKAMS T., FEVERY J., NEVENS F. A stable model of cirrhosis portal hypertension in the rat: thioacetamide revisited. Euro. J. Clin. Invest., 2006, 36, 242-9.
15. LI X., BENJAMIN IS., ALEXANDER B. Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. J. Hepatol., 2002, 36, 488-93. (Pubitemid 34407336)
16. MULLER A., MACHNIK F., ZIMMERMANN T., CHUBERT H. Thioacetamide-induced cirrhosislike liver lesions in rats-usefulness and reliability of this animal model. Exp. Pathol., 1988, 34, 22936.
17. MULLER P., POMORSKI T., PORWOLI S., TAUBER R., HERRMANN, A. Transverse movement of spin-labeled phospholipids in the plasma membrane of a hepatocytic cell line (HepG2): implications for biliary lipid secretion. Hepatology, 1996, 24, 497-503.
18. OE S., FUKUNAKA Y., HIROSE T., YAMAOKA Y., TABATA Y. A trial on regeneration therapy of rat liver cirrhosis by controlled release of hepatocyte growth factor. J. Control. Release., 2003, 88, 193-200. (Pubitemid 36287337)
19. PARRA OM., SILVA RS., SILVA JRM. C. HERNANDEZ-BLAZQUEZ FJ., PEDUTO L., SAAD WA., SAAD JUNIOR WA. Reduction of liver mass due to malnutrition in rats. Correlation with emanciation of animals and size of organs not inserted in the portal system, Rev. Pau.l Med., 1995, 113, 903-9.
20. PAWA S., ALI S. Liver necrosis and fulminant hepatic failure in rats: protection by oxyanionic form of tungsten. Biochim. Biophys. Acta, 2004, 1688, 210-22. (Pubitemid 38438524)
21. SATO M., MAKUBARI M., KAWAMURA M., SUGIMOTO J., MATSUMOTO K., ISHII T. The decrease in total collagen fibers in the liver by hepatocyte growth factor after formation of cirrhosis induced by thioacetamide. Biochem. Pharmacol., 2000, 59, 681-90. (Pubitemid 30085450)
22. SCHUPPAN D., STROBEL D., HAN EG. Hepatic fibrosis - Therapeutic strategies. Digestion, 1998, 59, 385-90. (Pubitemid 28360698)
23. SEONG J., HAN KH., PARK YN., NAM SH., KIM SH., KEUM WS., KIM KS. Lethal hepatic injury by combined treatment of radiation plus chemotherapy in rats with thioacetamide-induced liver cirrhosis. Internat. J. Radia.t Oncol., 2003, 57, 282-8. (Pubitemid 36959767)
24. SIMILE MM., BANNI S., ANGIONI E., CARTA G., DE MIGLI MR., MURONI MR., CALVISI DF., CARRU A., PASCALE RM., FEO F. 5'Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J. Hepatol., 2001, 34, 386-94. (Pubitemid 32240817)
25. SUN AY., INGELMAN-SUNDBERG M., NEVE E., MATSUMOTO H., NISHITANI Y., MINOWA Y., FUKUI Y., BAILEY SM., PATEL VB., CUNNINGHAM CC., ZIMA T., FIALOVA L., MIKULIKOVA L., POPOV P., MALBOHAN I., JANEBOVA M., NESPOR K., SUN GY. Etanol and oxidative stress. Clin. Exp. Res., 2001, 25, 237-43.
26. TANAKA H., UEDA H., FUKUCHI H., ICHINOSE M. Antifibrotic effect of edaravone in rat liver cirrhosis induced by dimethylnitrosamine. Clin. Exp. Med., 2009, doi: 10.1007/s10238-0090034-4.
27. TREY C., DAVIDSON CS. The management of fulminant hepatic failure. Prog. Liver. Dis., 1970, 3, 282-98.
28. TEWDT DC. Cirrhosis: a consequence of chronic liver disease. Vet. Clin. North Am. Small Anim. Pract., 1985, 15, 151-75.
29. ZIMMERMANN T., GARDEMANN A., MACHNIK G., DARGEL R., JUNGERMANN K. Metabolic and hemodynamic responses of bivascularly perfused rat liver to nerve stimulation, noradrenaline, acetylcholine and glucagon in thioacetamide-induced micronodular cirrhosis. Hepatology, 1992, 15, 464-70.
30. YONGPING M., PING L., GUANGLI D., JINXING D., GAOQIANG W., AIHUA L., LEI W., FENGHUA L. Action mechanism of Yi Guan Jian decoction on CCl4 induced cirhrosis in rats. J. Ethnopharmacol., 2009, 121, 35-42.
31. WANG X., LIU P., TANG A., LI F., LIU C., HU Y., XU L. Cordyceps mycelia extract decreases portal hypertension in rats with dimethylnitrosamine-induced liver cirrhosis: a study on its histological basis. J. Chin. Integr. Med., 2008, 6, 1136-42.
32. WATSON PJ. Chronic hepatitis in dogs: a review of current understanding of the aetiology, progression and treatment. Vet. J., 2004, 167, 238.